DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack
A federal court preliminarily approves a class action settlement for 2.3 million patients affected by the DaVita ransomware attack.
Stocks · News reference
TD Cowen Upgrades DaVita to Buy, Lowers Price Target to $220
TD Cowen analyst Ryan Langston upgrades DaVita (NYSE:DVA) from Hold to Buy and lowers the price target from $201 to $220.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.
Berkshire Hathaway Cut Capital One Stake by 58% in Q2 — Billionaire Dan Loeb Is Doing the Exact Opposite
Berkshire slashed its Capital One stake by 58%, among its largest cuts, despite the stock's top growth score.
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
Berkshire Hathaway holds nearly 45% of DaVita, a kidney dialysis healthcare company, representing its largest proportional equity stake—larger than Apple or American Express. Despite recent modest sell-offs in 2025, DaVita has surged over 56% year-to-date, driven by strong Q1 earnings that beat analyst expectations. The company offers consistent profitability, revenue growth, and an attractive forward P/E ratio of just over 12.